Skip to content
ChickenStockChickenStock
ResearchSCTX
Scribe Therapeutics logo

Scribe Therapeutics (SCTX) stock

NASDAQ

$16.30-4.06%(-0.69)

As of the Nov 13, 2026 close (U.S. Eastern)

Events and reference metrics · 1

Latest earnings

SEC filings

FY2026 Q3

Revenue in the latest quarter: $2M.

Key reported figures come first. Select one to see the same quarter across three years.

See the same quarter across three years →

Filed Nov 12, 2026 · 10-Q · SEC EDGAR

Reported results are from SEC EDGAR filings. Reference information only, not investment advice.

Insider transactions

Recent Form 4 filings grouped by person, date and transaction type.

14 SEC filings
  • Aghazadeh BehzadDirector · Jul 28, 2026Open-market purchase7,905 shares · $144K
    Avg. price $18.253,088,888 shares held after
  • GORDON CARL LDirector · Jul 27, 2026Open-market purchase1,000,000 shares · $15.0M
    Avg. price $151,348,825 shares held after
  • ORBIMED ADVISORS LLCDirector · Jul 27, 2026Open-market purchase1,000,000 shares · $15.0M
    Avg. price $151,348,825 shares held after
  • AH Bio Fund II, L.P.10% owner · Jul 27, 2026Open-market purchase333,333 shares · $5.0M
    Avg. price $152,385,075 shares held after
  • ORBIMED ADVISORS LLCDirector · Jul 27, 2026Conversion348,825 shares
    348,825 shares held after
  • AH Bio Fund II, L.P.10% owner · Jul 27, 2026Conversion2,749,392 shares
    Show 2 price lots
    • 2,051,742 sharesValue not reported
    • 697,650 sharesValue not reported
  • GORDON CARL LDirector · Jul 27, 2026Conversion348,825 shares
    348,825 shares held after
  • Doudna Jennifer A10% owner · Jul 27, 2026Conversion12,511 shares
    603,547 shares held after
  • Aghazadeh BehzadDirector · Jul 24, 2026Open-market purchase2,383,333 shares · $36.1M
    Avg. price $15.1534
    Show 2 price lots
    • 2,333,333 shares × $15$35.0M
    • 50,000 shares × $22.31$1.1M
  • Lucas SvetlanaChief Business Officer · Jul 23, 2026Open-market purchase3,000 shares · $45K
    Avg. price $153,000 shares held after
  • Parrot DavidChief Financial Officer · Jul 23, 2026Open-market purchase2,666 shares · $40K
    Avg. price $151,333 shares held after
    Show 2 price lots
    • 1,333 shares × $15$20K
    • 1,333 shares × $15$20K

Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.

Recent SEC filings

21 filings

Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.

Company overview

Expand ▾

Scribe Therapeutics (SCTX) stock information

NASDAQ

Scribe Therapeutics (SCTX) is listed on NASDAQ. These figures are computed in-house from official filings and are reference information only.

Scribe Therapeutics — frequently asked questions

Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.